pridopidine

Asset

Selective sigma-1 receptor agonist promoting neuroprotective pathways.

Stage: Phase 3
Modality: Small molecule
Target: SIGMAR1; 2
Indications: 2
Trials: 1
Developer

Indications

2

Amyotrophic lateral sclerosis
Phase 3, Recruiting, NCT07322003, clinicaltrials.gov, 7 Oct 2026
Huntington's disease
Phase 3, Recruiting, NCT07609108, clinicaltrials.gov, 8 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners2
Trials2
Competitors8
Signals2

Every asset’s record: target, stage, trials and the evidence behind it.

Updated 8 Oct 2026, 2 sources